USA - NASDAQ:TCRT - US98973P3091 - Common Stock
The current stock price of TCRT is 3.07 USD. In the past month the price increased by 26.86%. In the past year, price increased by 35.84%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.68 | 405.55B | ||
AMGN | AMGEN INC | 13.7 | 160.87B | ||
GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
ARGX | ARGENX SE - ADR | 91.01 | 51.63B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
INSM | INSMED INC | N/A | 35.04B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
NTRA | NATERA INC | N/A | 24.94B | ||
BIIB | BIOGEN INC | 8.93 | 20.97B |
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Houston, Texas and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
ALAUNOS THERAPEUTICS INC
2617 Bissonnet St, Suite 233
Houston TEXAS US
Employees: 1
Phone: 13463554099
The current stock price of TCRT is 3.07 USD. The price decreased by -0.97% in the last trading session.
The exchange symbol of ALAUNOS THERAPEUTICS INC is TCRT and it is listed on the Nasdaq exchange.
TCRT stock is listed on the Nasdaq exchange.
ALAUNOS THERAPEUTICS INC (TCRT) has a market capitalization of 6.72M USD. This makes TCRT a Nano Cap stock.
ALAUNOS THERAPEUTICS INC (TCRT) currently has 1 employees.
ALAUNOS THERAPEUTICS INC (TCRT) has a support level at 3.06 and a resistance level at 3.45. Check the full technical report for a detailed analysis of TCRT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TCRT does not pay a dividend.
ALAUNOS THERAPEUTICS INC (TCRT) will report earnings on 2025-11-12.
ALAUNOS THERAPEUTICS INC (TCRT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.46).
The outstanding short interest for ALAUNOS THERAPEUTICS INC (TCRT) is 3.67% of its float. Check the ownership tab for more information on the TCRT short interest.
ChartMill assigns a technical rating of 8 / 10 to TCRT. When comparing the yearly performance of all stocks, TCRT is one of the better performing stocks in the market, outperforming 79.01% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to TCRT. While TCRT has a great health rating, there are worries on its profitability.
Over the last trailing twelve months TCRT reported a non-GAAP Earnings per Share(EPS) of -2.46. The EPS decreased by -34.29% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -84.33% | ||
ROE | -109.07% | ||
Debt/Equity | 0 |